BioAge Labs financials
$7.14−0.56%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5M | $2.8M | $3.1M | $2.1M | $2.4M | $1.5M | $0.00 | $0.00 |
| Gross profit | $2.5M | $2.8M | $3.1M | $2.1M | $2.4M | $1.5M | $0.00 | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — |
| Operating income | -$29.3M | -$25.4M | -$28.4M | -$23.1M | -$24.8M | -$16.4M | -$25.4M | -$24.8M |
| Net income | -$26.1M | -$22.3M | -$25.9M | -$20.2M | -$21.6M | -$12.9M | -$21.1M | -$23.4M |
| Net margin | −1064.7% | −802.8% | −842.9% | −982.0% | −894.0% | −891.0% | — | — |
| Diluted EPS | $-0.58 | $-0.52 | $-0.72 | $-0.56 | $-0.60 | $-0.36 | $-0.59 | $-6.70 |
| EBITDA | -$29.3M | -$25.3M | -$28.4M | -$23.1M | -$24.7M | -$16.4M | -$25.3M | -$24.7M |
| Operating cash flow | -$19.3M | -$24.0M | -$28.3M | -$16.0M | -$20.0M | -$17.4M | -$5.1M | -$14.9M |
| Free cash flow | -$19.6M | -$24.1M | -$28.4M | -$16.1M | -$20.1M | -$17.8M | -$5.2M | -$15.2M |
| Diluted shares | 44.8M | 42.5M | 36.2M | 35.9M | 35.9M | 35.9M | 36.0M | 3.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $74.0M | $241.8M | $188.9M | $215.6M | $220.3M | $257.5M |
| Short-term investments | $244.8M | $141.4M | $92.2M | $70.2M | $77.0M | $63.0M |
| Total debt | $0.00 | $1.2M | $2.6M | $4.1M | $5.6M | $7.1M |
| Total assets | $396.9M | $397.7M | $294.9M | $305.1M | $322.1M | $343.8M |
| Total liabilities | $22.0M | $18.5M | $22.8M | $27.6M | $27.4M | $30.7M |
| Shareholders' equity | $374.9M | $379.1M | $272.1M | $277.5M | $294.8M | $313.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology